SCHEMBL49594

SCHEMBL49594

N=C(N)c1ccc(CN)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 2/20 1.00
F10 P00742 2/20 1.00
ST14 Q9Y5Y6 4/20 0.69
PRSS1 P07477 5/20 0.67
PRSS3 P35030 4/20 0.67
PRSS2 P07478 3/20 0.67
PLAU P00749 4/20 0.56
F2 P00734 7/20 0.55
TMPRSS6 Q8IU80 1/20 0.55
LMNA P02545 1/20 0.54
MASP2 O00187 1/20 0.54
THPO P40225 1/20 0.54
PLG P00747 2/20 0.53
C1S P09871 1/20 0.53
APEX1 P27695 1/20 0.52
PLAT P00750 1/20 0.51
KLKB1 P03952 1/20 0.51
ABAT P80404 1/20 0.50
F12 P00748 1/20 0.50
F7 P08709 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL322008 0.98 LOXL2 (0.95) LOXL2F10ST14PRSS1PRSS3
Hydrochloric Acid SCHEMBL1981173 0.98 LOXL2 (0.95) LOXL2F10ST14PRSS1PRSS3
Hydrochloric Acid SCHEMBL10925118 0.91 LOXL2 (0.83) LOXL2F10ST14PRSS1PRSS3
Hydrochloric Acid SCHEMBL10919747 0.86 LOXL2 (0.74) LOXL2F10ST14PRSS1PRSS3
Hydrochloric Acid SCHEMBL10919741 0.86 LOXL2 (0.74) LOXL2F10ST14PRSS1PRSS3
Hydrochloric Acid SCHEMBL27771922 0.84 LOXL2 (0.71) LOXL2F10ST14PRSS1PRSS3
SCHEMBL10922350 0.83 F2 (0.86) LOXL2F10ST14PRSS1PRSS3
SCHEMBL2717268 0.82 PRSS1 (0.70) LOXL2F10ST14PRSS1PRSS3
SCHEMBL17887806 0.82 PRMT1 (0.80) LOXL2F10ST14PRSS1PLAU
SCHEMBL7815090 0.81 F10 (0.68) LOXL2F10ST14PRSS1PRSS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 517 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3854406-B1 TUBE FOR THE PREPARATION OF WOUND HEALANT COMPOSITION REGEN LAB SA (CH) 2023-07-26 EP claimed
US-11207282-B2 Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2021-12-28 US claimed
EP-3154941-B1 SMALL MOLECULE LFA-1 INHIBITORS ALLOCYTE PHARMACEUTICALS AG (CH) 2021-01-20 EP claimed
US-20200261386-A1 TUNEABLE DELIVERY OF NANOPARTICLE BOUND ACTIVE PLASMIN FOR THE TREATMENT OF THROMBOSIS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION 2020-08-20 US claimed
US-20190040008-A1 SMALL MOLECULE LFA-1 INHIBITORS ALLOCYTE PHARMACEUTICALS AG (CH) 2019-02-07 US claimed
US-10077238-B2 Small molecule LFA-1 inhibitors ALLOCYTE PHARMACEUTICALS AG (CH) 2018-09-18 US claimed
US-20180147044-A1 TUBULAR WOVEN CONSTRUCT TORAY INDUSTRIES, INC. (JP) 2018-05-31 US claimed
CN-105979910-B Artificial blood vessel 东丽株式会社 2018-05-18 CN claimed
EP-3305336-A1 TUBULAR WOVEN FABRIC STRUCTURE Toray Industries, Inc. (JP) 2018-04-11 EP claimed
CN-107614024-A tubular fabric structure 东丽株式会社 2018-01-19 CN claimed
US-20070179083-A1 Covalent attachment of ligands to nucleophilic proteins guided by non-covalent binding COVALENT BIOSCIENCE INCORPORATED 2007-08-02 US claimed
EP-1610808-A2 COVALENT ATTACHMENT OF LIGANDS TO NUCLEOPHILIC PROTEINS GUIDED BY NON-COVALENT BINDING University of Texas Medical School (US) 2006-01-04 EP claimed
EP-0869966-B1 PRODRUGS OF THROMBIN INHIBITORS ASTRAZENECA AB (SE) 2005-03-16 EP claimed
WO-2004087059-A2 COVALENT ATTACHMENT OF LIGANDS TO NUCLEOPHILIC PROTEINS GUIDED BY NON-COVALENT BINDING THE UNIVERSITY OF TEXAS (US) 2004-10-14 WO claimed
US-6716834-B2 ANTICOAGULANTS. ASTRAZENECA AB (SE) 2004-04-06 US claimed
EP-1283837-B1 NEW THIOCHROMANE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS ASTRAZENECA AB (SE) 2004-02-25 EP claimed
US-20030220317-A1 Thiochromane derivatives and their use as thrombin inhibitors ASTRAZENECA AB (SE) 2003-11-27 US claimed
US-6433186-B1 TREATMENT OF CONDITIONS WHERE INHIBITION OF THROMBIN IS REQUIRED (E.G. THROMBOSIS) OR AS ANTICOAGULANTS. ASTRAZENECA AB (SE) 2002-08-13 US claimed
US-20020068730-A1 New amidino derivatives and their use as thormbin inhibitors ASTRAZENECA AB (SE) 2002-06-06 US claimed
EP-0377229-B1 Use of specific properties of allergens from animal sources and methods for their isolation LETI LAB (ES) 1996-06-26 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220317-A1 Thiochromane derivatives and their use as thrombin inhibitors SERPINC1, F2, TFPI LOXL2 2577/4885F10 76/4885ST14 988/4885
US-11207282-B2 Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis PLAT, PLG, PLAUR LOXL2 747/4885F10 53/4885ST14 838/4885
US-10077238-B2 Small molecule LFA-1 inhibitors ICAM1, VCAM1, ITGB1 LOXL2 1647/4885F10 920/4885ST14 1628/4885
US-20070179083-A1 Covalent attachment of ligands to nucleophilic proteins guided by non-covalent binding FABP1, FPR1, ADGRF1 LOXL2 115/4885F10 882/4885ST14 3041/4885
US-20190040008-A1 SMALL MOLECULE LFA-1 INHIBITORS ICAM1, VCAM1, ITGB1 LOXL2 1647/4885F10 920/4885ST14 1628/4885
US-20020068730-A1 New amidino derivatives and their use as thormbin inhibitors SERPINC1, SERPINE1, ADAMTS1 LOXL2 1850/4885F10 136/4885ST14 712/4885
US-20200261386-A1 TUNEABLE DELIVERY OF NANOPARTICLE BOUND ACTIVE PLASMIN FOR THE TREATMENT OF THROMBOSIS PLAT, PLG, PLAUR LOXL2 747/4885F10 53/4885ST14 838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.